Table 3.
Thrombotic and hemorrhagic events.
| No Enoxaparin treatment | Enoxaparin (prophylactic) | Enoxaparin (therapeutic) | p value | ||
|---|---|---|---|---|---|
| Patients | N (%) | 604 (43) | 487 (35) | 312 (22) | |
| Thrombotic events | N (%) | 13 (2·2) | 12 (2·5) | 51 (16) | <0·001 |
| Pulmonary Embolism | 1 | 3 | 29 | ||
| Venous thromboembolism | 2 | 1 | 14 | ||
| Acute myocardial infarction | 6 | 4 | 6 | ||
| Cerebral infarction | 4 | 4 | 2 | ||
| Hemorrhagic events | N (%) | 15 (2·5) | 6 (1·2) | 10 (3·2) | 0·12 |
Recorded thrombotic and hemorrhagic events in the two cohorts. Patients in the enoxaparin cohort are divided according to dosage of received: prophylactic ≤ 40 mg a day or therapeutic > 40 mg a day. P values were computed with Fisher's exact test.